Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3

NCT: NCT07589387 · NOT_YET_RECRUITING

NCT IDNCT07589387
StatusNOT_YET_RECRUITING
Start Date2026-05-01
Completion2030-01-31

Brief Summary

The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary healthcare centers (PHCs) in the Federal Capital Territory (FCT). This program demonstrated significant improvements in hypertension treatment and control. The focus of aim 3 will be evaluating diabetes management through the implementation of the HEARTS-D bundle in 10 PHCs across the FCT that previously participated in the initial HTN Program.

Frequently Asked Questions

What is Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3?

Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3 is a clinical trial registered under NCT07589387. Current status: NOT_YET_RECRUITING.

What is the status of NCT07589387?

The current status of NCT07589387 (Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3) is: NOT_YET_RECRUITING.

When did Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3 start?

Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3 started on 2026-05-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑